Introduction
It has generally been recommended [1] [2] [3] that screening for hyperaldosteronism be considered for at least hypertensive patients with spontaneous hypokalaemia (Ko3.5 mmol/l), hypertensive patients with marked diuretic-induced hypokalaemia (Ko3.0 mmol/l), patients with hypertension refractory to treatment with three or more drugs or hypertensive patients found to have an incidental adrenal adenoma. Although primary hyperaldosteronism was previously believed to account for less than 1% of hypertensive patients and hypokalaemia was considered a prerequisite for pursuing diagnostic tests, 3 recent studies pursuing screening of both hypokalaemic and normokalaemic hypertensives have reported a much higher prevalence of this disease, with primary hyperaldosteronism accounting for up to 12% of hypertensive patients and most patients being normokalaemic. [4] [5] [6] [7] [8] Therefore, primary hyperaldosteronism could be the most common identifiable, specifically treatable and potentially curable form of hypertension. It was previously thought that it was only worthwhile to perform diagnostic workup for primary hyperaldosteronism in hypokalaemic patients in the belief that the great majority of patients with normokalaemic primary hyperaldosteronism have bilateral adrenal hyperplasia rather than aldosterone-producing adenoma and are therefore rarely surgically curable. 9 However, retrospective evaluation of the diagnosis of primary hyperaldosteronism from clinical centers in five continents suggest that the application of a widespread screening strategy to a greater number of hypertensives will lead to a 5-to 15-fold increase in the identification of patients affected by primary hyperaldosteronism. 10 Only a small proportion of patients (between 9 and 37%) are hypokalaemic and the annual detection rate of aldosterone-producing adenoma (APA) increased in all centers by up to six times after the widespread application of screening. 10 Overall, it seems therefore that the widespread screening of all hypertensive patients will lead to a marked increase in the detection rate of primary hyperaldosteronism. Indeed, the decision taken by the Brisbane group to screen all (and not just hypokalemic or resistant) hypertensives led to a 10-fold increase in detection rate of primary hyperaldosteronism and four-fold increase in removal rate of APAs.
Increased detection not only allows increased diagnosis of primary hyperaldosteronism but can help toward optimizing antihypertensive therapy in individual patients with hypertension and thereby potentially reduce costs by decreasing the number of drugs required. The prescription of antihypertensive therapy based on the renin profile of the patient has resulted in a mean reduction of 0.6 drugs (from 2.1 to 1.5) per patient, compared with a random prescription, 12 which is in turn associated with reductions in cost (À20%) and side effects. Furthermore, such a strategy allows a diagnosis of secondary hypertension in a fifth of such patients, half of whom are indeed patients with primary hyperaldosteronism. 12 Owing to poor sensitivity and specificity, (up to 60% of patients with primary aldosteronism may have normal plasma aldosterone concentrations 13 ), measures of renin and aldosterone by themselves are considered to have limited value in screening for primary aldosteronism. Hiramatsu et al.
14 first proposed the computation of the plasma aldosterone concentration (PA) to plasma renin activity (PRA) ratio (ARR) for evaluation of primary hyperaldosteronism in 1981. Today, calculation of this ratio, which reduces these measures to a single number, is widely advocated as a useful screening method 15, 16 because it presents less day-to-day fluctuation than either plasma aldosterone or plasma renin activity. 17 However, it is difficult to make out from the literature what are the operating characteristics or optimum threshold levels for the ARR. A review of the literature up to October 2001 that included 16 studies with 3136 participants demonstrated ARR cutoff values that ranged widely from 200 to 2774 pmol/l per mg/l/h. 18 As the predictive value of the ARR is dependent on the threshold used with a higher ARR making the diagnosis of primary aldosteronism more likely, 19 the higher the threshold, the more specific the ARR with a concomitant loss in sensitivity. We therefore decided to extract relevant information from the literature on this topic and make recommendations for clinical use. To establish the most inclusionary literature set possible, extensive systematic searches were conducted of PubMed, starting with the MeSH term 'Hyperaldosteronism/diagnosis' followed by hand searches of selected journals, author searches, and searches of selected reference lists, especially of review articles.
Operating characteristics and threshold value
To compute this ratio, blood is drawn for PA & PRA after 2 h of ambulation, but preferably at 0800 h, since at that time plasma aldosterone is normally at its highest level. In healthy volunteers, the range of the ARR (ng/dl per mg/l/h) is 2-17 with a mean of 5.5 (50-470, mean 150 when aldosterone is expressed as pmol/l). 20 Others report higher values in healthy volunteers but usually ARR not exceeding 21-34 (amounting to a ratio of 580-940 when plasma aldosterone is expressed as pmol/l). 13, 21 In essential hypertensives too, the ARR is usually less than this and remains within this range during antihypertensive treatment.
14,17 A recent study concluded that if the ARR value is less than 23.6 ng/dl per mg/l/h (o650 if PA in pmol/l), clinicians can be assured that the likelihood of primary hyperaldosteronism is extremely low 17 so we can be confident that patients with later proven APA or idiopathic hyperaldosteronism (IHA) usually will have an ARR above 25-34 (690-940 if plasma aldosterone is expressed in pmol/l) ( Table 1) . 13, 17, 21 It has been shown that the ARR has greater than 90% sensitivity 22 around a threshold of the ratio of 30 (830 if plasma aldosterone is expressed in pmol/l), 15 and a negative predictive value of 93-99%. This makes it possible to confirm a definitive diagnosis of primary aldosteronism in a significant proportion of such normokalaemic hypertensive patients, leading to a remarkable increase in the rate of diagnosis. 24 Using this sensitive test threshold to screen unselected hypertensive patients, the prevalence of primary aldosteronism in this group is over 10%. 4 As the cutoff is increased to 50 (1380 if PA in pmol/l) for the ARR, there is a significantly lower negative predictive value (drops by a third from the cutoff of 30) but far less false-positive diagnoses are made. 8, 25 Above 66.9 ng/dl per ng/ml/ h (41850 if PA in pmol/l), the diagnosis of primary hyperaldosteronism can practically be considered established 17 although now the negative predictive value is poor.
Quantitative studies using ROC analysis of the ARR suggest that combining this ratio with a PA threshold might improve diagnostic discrimination of APA and IHA from low-renin essential hypertension (LREH) 25 and overcome renin dependency of the ratio because when plasma renin levels are very low, plasma aldosterone levels as low as 114 pmol/l might result in a positive ARR. 26, 27 Using the combined ROC-defined cutoff points of 27-30 for the ARR (750 if PA in pmol/l) and 12 ng/dl (330 pmol/l) for aldosterone, the reported discrimination of patients with primary aldosteronism (APA and IHA) from those with low-renin essential hypertension was with greater than 90% sensitivity and specificity. 25 Weinberger, also has suggested that an ARR 430 (830 if PA is expressed in pmol/l) with an absolute PA 4420 pmol/l (15 ng/dl) might not need a confirmatory study. 15 Caution is advised here, however, since although such a strategy increases the specificity of the test (i.e., decreases the number of false positives), it also markedly decreases sensitivity (i.e., increases the number of false negatives). For example, it has been shown that imposition of a threshold value of aldosterone of 420 nmol/l (15 ng/dl), as suggested by the authors in the above-cited studies, to the optimum ARR threshold increased the specificity of the ARR from 74 to 97% but markedly decreased the sensitivity from 73 to 33%. 22 Thus, based on this finding, such a strategy may be ill advised in screening for primary aldosteronism. 22 It has been suggested that since patients with an APA are the sole ones who will benefit from surgery, they can be identified (positive predictive value of 90%) and separated from other causes (IHA and LREH) of the low-renin hypertension syndrome using a higher combined cutoff values for the ARR 4100 (42760 if PA in pmol/l) and PAC (420 ng/dl; 4550 pmol/l) which has a positive predictive value of 89.5% in discriminating APA from IHA (with 84% sensitivity and 82.6% specificity). 25 It is unlikely, however, that APA can be distinguished from IHA based solely on a high ARR. Although a high ratio is likely very specific for APA, its negative predictive value remains questionable. Also, the latter study was a retrospective analysis of data collected over a 15-year period. Although adenomas were confirmed by surgical excision, the absence of an adenoma was presumed based on negative CT findings as opposed to adrenal vein sampling. More recent studies indicate that CT imaging is not a very reliable method of excluding APA and therefore AVS is probably necessary to exclude APA.
Captopril enhancement
Measurement of the ARR 60-120 min after a single dose of 25-50 mg of captopril might enhance diagnostic discrimination 28 by increasing specificity and decreasing the number of false positives. [28] [29] [30] The use of captopril therefore increases the utility of the ARR by increasing specificity and thus decreasing the need for confirmatory testing. In 1983, Lyons et al. 30 compared the use of the ARR obtained 2 h after a dose of captopril with results obtained using the 'gold standard' saline infusion. They found that the acute suppression of aldosterone and removal of any negative feedback on circulating levels of renin using the post captopril ARR were as efficacious as the more cumbersome infusion of saline over a 4 h period. They also found that the plasma aldosterone is usually less than 15 ng/dl (415 pmol/l) in all normotensive subjects and in 9 of 10 essential hypertensives, while it remained above this threshold in all 6 patients with APA and in 4 of 5 with IHA. More recently, Agharazii et al. 31 published a detailed comparison of the captopril test and 3 days of high-salt loading in 49 patients with a presumed diagnosis of primary aldosteronism. These investigators demonstrated that the captopril test is as efficacious in confirming the diagnosis as is the 'gold standard' test of 3 days of oral salt loading. Thus, the captopril-stimulated ARR seems to have now been confirmed using two different 'goldstandard' salt-loading tests. 30, 31 The simple addition of 25 mg oral captopril 2 h before obtaining a second set of blood samples for the ARR, therefore, not only serves as a screening test but also might establish a definitive diagnosis of primary aldosteronism. 32 The specificity of the ARR test is more dependent on demonstrating that the post-captopril ARR remains above 12 (330 if PA in pmol/l), despite the loss of the inhibitory levels of angiotensin II, and the PA fails to be suppressed to less than a definable level (o240-330 pmol/l). 31, 32 This test saves time and money and could lead directly to definitive studies localizing the lesion (Figure 1 ).
Plasma renin concentration
The plasma renin concentration (PRC) is replacing the PRA as a measure of renin in clinical practice. It seems that the lower limit of the PRC assay increases in numerical value and this may necessitate a lower cutoff for the ARR. Although one study with a fully automated system and two studies with manual PRC assays for screening for primary hyperaldosteronism have been published, [33] [34] [35] the comparison with data from the literature is limited. Trenkel et al. 33 suggested a cutoff value of 50 (aldosterone measured in serum by RIA, expressed in ng/l; PRC measured by IRMA, expressed in ng/l), which corresponds to 83 pmol/mU (for PRC, 1 mU/l ¼ 0.6 ng/l 34 ). Ferrari et al. 35 and Racine et al. 36 recommended a cutoff of 140-150 (PA in pmol/l and PRC in ng/l) corresponding to 84-90 pmol/mU. Perschel et al. 34 produced a tentatively proposed cutoff value of 71 pmol/mU. Subsequent studies including essential hypertensive cohorts may necessitate readjustment, although there is good concordance with the recommendations made by Trenkel et al.
33
, Ferrari et al. 34 and Perschel et al. 35 The equivalent cutoff for the ratio using PRC in mU/l (480) is therefore approximately one-tenth of the ratio derived using PRA in mg/l/h (4800).
Pitfalls
Subjects ingesting large amounts of sodium, patients with renal impairment or those taking beta-adrenoceptor blockers can have false-positive results. 37 Salt restriction, ingestion of spironolactone and other diuretics, especially potassium-wasting diuretics can lead to false-negative results. Optimal performance of this test consists of eliminating other factors that can affect renin and aldosterone such as correction of hypokalaemia with potassium chloride supplements, cessation of diuretics and beta blockers. It was initially recommended to avoid or stop all antihypertensive treatments for at least 2 weeks, especially beta-blockers and ACEI which could give false-positive or false-negative values, respectively. However, the ratio is more sensitive than screening by either determination considered singly and appears to be less affected by drug administration, day-to-day and diurnal variation and by the position of the subjects, thus allowing its use under random conditions. 13 Caution should be exercised in recognizing falsely elevated values in patients with renal failure (5 of 17 patients with renal failure presented with a ratio above the limit of 34); 13 furthermore, there is the possibility of false-positive values under treatment with beta-blocking agents or diuretics or when aldosterone is abruptly stimulated by potassium administration resulting in a stimulation of aldosterone biosynthesis and a lowering of PRA, 38 and false-negative values under treatment with ACEI and perhaps calcium antagonists, although in the long term, in contrast to their acute effect, these agents appear to affect neither renin nor aldosterone. 39 Workers have investigated the effects of therapy with atenolol, amlodipine, doxazosin, fosinopril, and irbesartan on the aldosterone renin ratio in a group of 230 patients with suspected primary aldosteronism. 8 The percent change from control of ARR in patients taking amlodipine was À17%732; atenolol, 62%782; doxazosin, À5%726; fosinopril, À30%724; and irbesartan, À43%727. The ARR change induced by atenolol was significantly higher compared with that induced by all other drugs, and the ARR change induced by irbesartan was significantly lower than that induced by doxazosin. One of 55 patients from the group taking amlodipine (1.8%) and 4/17 of the patients taking irbesartan (23.5%) gave a false-negative ARR (o50). None of the patients of the groups taking fosinopril, doxazosin, and atenolol displayed a false-negative ARR. It seems that alpha-blockers (doxazosin) and calcium Optimal use and interpretation of the aldosterone renin ratio SAR Doi et al channel blockers (amlodipine) can be used in hypertensive patients who need to undergo aldosterone and PRA measurement for the diagnosis of primary aldosteronism. Beta-Blockers can be responsible for an increased rate of false-positive aldosterone renin ratio's and ACEI/ARB for increased false negative ratios. Beta-blockers and aldosterone antagonists have the strongest impact on the renin-angiotensin system (Table 2) . 40 
Confirmatory testing
Usually the ARR ratio is repeated at least thrice 41 as primary hyperaldosteronism may occur in hypertensive patients despite a normal renin/aldosterone profile on limited occasions. If positive (ARR4800 (pmol/l)/(mg/l/h) or PA/PRC480 pmol/mU or PA/ PRC4130 pmol/ng) this is followed by a confirmatory suppression or stimulation test. 3, 42 This is because with the ARR up to a quarter of subjects may have false-positive results 22 with a corresponding positive predictive value of 33-56% (but a negative predictive value of 93-99%). 22, 23 Even among African-American subjects, where the ARR is less sensitive than in white subjects (75 vs 80%), it still had a high negative predictive value (92 vs 94%) 23 suggesting that while the ARR is valid as a screening test for primary hyperaldosteronism in African American and white patients on stable antihypertensive treatments, there will be significant false-positivity and a high ratio while suggestive of primary hyperaldosteronism, must be confirmed (Table 3) . 43 Upright PAC 4166 pmol/l and PRA o1.0 mg/l/h at 10 am on day 4, coupled with normal plasma potassium levels, cortisol at 1000 hours no greater than at 0700 hours on day 4, and urinary sodium 43 mmol/kg/day on day 3 Intravenous saline load 6, 10, 53, 55, 56 Intravenous infusion of 2 l of 0.9% sodium chloride solution over 4 h (500 ml/h) Plasma aldosterone after infusion 4236 pmol/l (140-235 pmol/l grey zone) Oral sodium load 10, 20, 22 Oral sodium chloride supplementation (300 mmol of sodium per day for 3 days) and potassium supplementation (if required) Urinary aldosterone on the third day 439 nmol (412 mg) in 24 h, and urinary sodium 4200 mmol in 24 h ARR after captopril 31, 32 A second determination of the ARR 2 h after oral 25 mg captopril Post-captopril ARR 412 (ng/dl)/(mg/l/h) AND PA 4 330 pmol/l Renin stimulation test 44, 47, 48 Furosemide 40 mg orally every 8 h the proceeding day and 0800 hours the next day followed by 2 h ambulation and sampling of renin. OR i.v. furosemide 40 mg and ambulation for 2 h followed by sampling of renin PRA remains below 1.7 mg/l/h (PRC below 14 mU/l or 8 ng/l) Abbreviations: ARR: plasma aldosterone concenteration to plasma renin activity ratio; PA: plasma aldosterone concenteration; PRA: plasma renin ativity.
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The suppression type of confirmatory testing is aimed at demonstrating autonomy of aldosterone secretion and is commonly utilized and comprise basically of sodium loading (and measurement of serum or urinary aldosterone) or fludrocortisone suppression of PA. However, false-negative results are likely to occur in cases of overproduction of aldosterone which is responsive to angiotensin II (IHA and angiotensin II-responsive APA). Furthermore, in elderly patients and patients with severe hypertension, sodium loading is not without risk. An alternative therefore, is the use of captopril loading as previously discussed and demonstrating failure to decrease the ARR ratio below 12 ng/dl/mg/ l/h (330 pmol/l per mg/l/h or 33 pmol/mU) in combination with a failure to decrease PA below 240-330 pmol/l.
Another alternative is the stimulation of PRA or PRC. [44] [45] [46] [47] [48] This is done using furosemide 40 mg given orally eight hourly the preceding day and in the morning followed after 2 h of upright ambulation by blood sampling for PRA at 0800 hours. After such a hypovolaemic stimulation, PRA remains suppressed. It is easily performed with the subject ambulatory, requires only one blood sample, and it is not necessary to stop antihypertensive treatment except for beta-blocking agents. It offers the advantage of a simple and safe confirmatory test, not just for primary aldosteronism, but also for the syndrome of apparent mineralocorticoid excess, DOC-producing adenoma, and even in Liddle's syndrome. More recently, 44 renin stimulation has been assessed by measurement of PRA after patients have been supine for 30 min, and again after an i.v. bolus of 40 mg furosemide followed by 1 h or 2 h in an upright posture. These authors found that renin stimulation by the frusemide and upright posture may not be as accurate or effective as the ARR in distinguishing APA vs non-APA in low-renin hypertensives 44 although it is not clear from the study whether the non-APA group included only IHA or some lowrenin essential hypertensives. It is likely, based on the data they presented, that these were all mainly patients with primary hyperaldosteronism and their data 44 suggests a post stimulation cutoff for lowrenin hypertension be placed at 0.5 ng/l/s which is 1.7 ng/ml/h and equivalent to a PRC of 14 mU/l or 8 ng/l.
Conclusion
Altogether the computation of the ARR, particularly when correlated to the PA value, 30 appears the most robust screening test for primary aldosteronism. 24 Now that plasma aldosterone and renin assessments are readily available in most commercial laboratories and major hospitals at a reasonable cost, measurement of these parameters in simultaneously drawn blood samples is recommended, followed by computation of the ARR (Figure 1 ). Usually the ARR ratio is repeated at least once and if positive (ARR4800 (pmol/l)/(mg/l/h) or 480 pmol/mU or 4130 pmol/ng) is followed by a confirmatory suppression or stimulation test. Above 66.9 ng/dl per mg/l/h (41850 if PA in pmol/l), the diagnosis of primary hyperaldosteronism can practically be considered established 17 and no confirmatory testing is required (Figure 1 ).
